SB 2384 North Dakota Senate · 68th Legislative Assembly (2023-24)

A BILL for an Act to provide for a legislative management study relating to vaccines for respiratory syncytial virus and vaccines developed using messenger ribonucleic acid technology.

Summary

Relating to vaccines for respiratory syncytial virus and vaccines developed using messenger ribonucleic acid technology.

Bill status passed 3 of 5 stages cleared

Introduction

Jan 2023

Committee Review

Apr 2023

Senate Passage

Feb 2023

House Failed

Apr 2023

Governor

Introduced Jan 23, 2023 Last action Apr 4, 2023

Floor votes · Senate Feb 9, 2023 · House Apr 4, 2023

How they voted

25–22

Passed

Total votes 47

Feb 9, 2023

D Democratic4

4 Nay

100% Nay

R Republican43

25 Yea 18 Nay

58% Yea

Vote distribution

All Yea All Nay Mixed No data

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Amendments

Apr 4, 2023

Vote failed

House Vote: fail (36-46-2)

house

Apr 3, 2023

Lower · Passed

Reported back, do not pass, placed on calendar 7 6 1

lower

Apr 3, 2023

Lower · Passed

Committee Hearing 03:30

lower

Mar 15, 2023

Lower · Passed

Committee Hearing 02:30

lower

Feb 17, 2023

Introduced

Introduced, first reading, referred Human Services Committee

lower

Feb 9, 2023

Upper · Passed

Second reading, passed, yeas 25 nays 22

upper

Feb 9, 2023

Upper · Passed

Amendment adopted

upper

Feb 9, 2023

Introduced

Amendment proposed on floor

upper

Feb 9, 2023

Upper · Passed

Reported back, do not pass, placed on calendar 6 0 0

upper

Feb 8, 2023

Upper · Passed

Committee Hearing 03:44

upper

Feb 7, 2023

Upper · Passed

Committee Hearing 09:30

upper

Jan 23, 2023

Introduced

Introduced, first reading, referred Human Services Committee

upper

1 primary · 3 co-sponsors